Sodium/iodide cotransporter

Last updated
SLC5A5
Identifiers
Aliases SLC5A5 , NIS, TDH1, solute carrier family 5 member 5
External IDs OMIM: 601843 MGI: 2149330 HomoloGene: 37311 GeneCards: SLC5A5
Orthologs
SpeciesHumanMouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)

NM_000453

NM_053248

RefSeq (protein)

NP_000444

NP_444478

Location (UCSC) Chr 19: 17.87 – 17.9 Mb Chr 8: 71.34 – 71.35 Mb
PubMed search [3] [4]
Wikidata
View/Edit Human View/Edit Mouse

The sodium/iodide cotransporter, also known as the sodium/iodide symporter (NIS), [5] is a protein that in humans is encoded by the SLC5A5 gene. [6] [7] [8] It is a transmembrane glycoprotein with a molecular weight of 87 kDa and 13 transmembrane domains, which transports two sodium cations (Na+) for each iodide anion (I) into the cell. [9] NIS mediated uptake of iodide into follicular cells of the thyroid gland is the first step in the synthesis of thyroid hormone. [9]

Contents

Iodine uptake

Iodine uptake mediated by thyroid follicular cells from the blood plasma is the first step for the synthesis of thyroid hormones. This ingested iodine is bound to serum proteins, especially to albumins. [10] [11] The rest of the iodine which remains unlinked and free in bloodstream, is removed from the body through urine (the kidney is essential in the removal of iodine from extracellular space).

Iodine uptake is a result of an active transport mechanism mediated by the NIS protein, which is found in the basolateral membrane of thyroid follicular cells. As a result of this active transport, iodide concentration inside follicular cells of thyroid tissue is 20 to 50 times higher than in the plasma. [12] The transport of iodide across the cell membrane is driven by the electrochemical gradient of sodium (the intracellular concentration of sodium is approximately 12 mM and extracellular concentration 140 mM). [13] Once inside the follicular cells, the iodide diffuses to the apical membrane, where it is metabolically oxidized through the action of thyroid peroxidase to iodinium (I+) which in turn iodinates tyrosine residues of the thyroglobulin proteins in the follicle colloid. Thus, NIS is essential for the synthesis of thyroid hormones (T3 and T4). [14]

Thyroid hormone synthesis, with the Na/I symporter seen at right. Thyroid hormone synthesis.png
Thyroid hormone synthesis, with the Na/I symporter seen at right.

Apart from thyroid cells NIS can also be found, although less expressed, in other tissues such as the salivary glands, the gastric mucosa, the kidney, the placenta, the ovaries and the mammary glands during pregnancy and lactation. [15] [16] NIS expression in the mammary glands is quite a relevant fact since the regulation of iodide absorption and its presence in the breast milk is the main source of iodine for a newborn. Note that the regulation of NIS expression in thyroid is done by the thyroid-stimulating hormone (TSH), whereas in breast is done by a combination of three molecules: prolactin, oxytocin and β-estradiol. [17]

Inhibition by Environmental Chemicals

Some anions like perchlorate, pertechnetate and thiocyanate, can affect iodide capture by competitive inhibition because they can use the symporter when their concentration in plasma is high, even though they have less affinity for NIS than iodide has. Many plant cyanogenic glycosides, which are important pesticides, also act via inhibition of NIS in a large part of animal cells of herbivores and parasites and not in plant cells. Some evidence suggests that fluoride, such as that present in drinking water, may decrease cellular expression of the sodium/iodide symporter. [18]

Using a validated in vitro radioactive iodide uptake (RAIU) assay, [19] the Besides the traditionally known anions such as perchlorate, organic chemicals may also pose inhibition of iodide uptake via NIS. [20]

Regulation in iodine uptake

The iodine transport mechanisms are closely submitted to the regulation of NIS expression. There are two kinds of regulation on NIS expression: positive and negative regulation. Positive regulation depends on TSH, which acts by transcriptional and posttranslational mechanisms. On the other hand, negative regulation depends on the plasmatic concentrations of iodide. [21]

Transcriptional regulation

At a transcriptional level, TSH regulates the thyroid's function through cAMP. TSH first binds to its receptors which are joined to G proteins, and then induces the activation of the enzyme adenylate cyclase, which will raise the intracellular levels of cAMP. [22] This can activate the CREB transcription factor (cAMP Response Element-Binding) that will bind to the CRE (cAMP Responsive Element). However, this might not occur and, instead, the increase in cAMP can be followed by PKA (Protein kinase A) activation and, as a result, the activation of the transcription factor Pax8 after phosphorylation. [23]

These two transcription factors influence the activity of NUE (NIS Upstream Enhancer), which is essential for initiating transcription of NIS. NUE's activity depends on 4 relevant sites which have been identified by mutational analysis. The transcriptional factor Pax8 binds in two of these sites. Pax8 mutations lead to a decrease in the transcriptional activity of NUE. [24] Another binding-site is the CRE, where the CREB binds, taking part in NIS transcription.

In contrast, growth factors such as IGF-1 and TGF-β (which is induced by the BRAF-V600E oncogene) [25] suppress NIS gene expression, not letting NIS localize in the membrane.

Posttranslational regulation

The TSH can also regulate the iodide uptake at a posttranslational level, since, if it's absent, the NIS can be resorted from the basolateral membrane of the cell in to the cytoplasm where it is no longer functional. Therefore, the iodide uptake is reduced. [26]

Thyroid diseases

The lack of iodide transport inside follicular cells tends to cause goitres. There are some mutations in the NIS DNA that cause hypothyroidism and thyroid dyshormonogenesis. [27]

Moreover, antibodies anti-NIS have been found in thyroid autoimmune diseases. [28] Using RT-PCR tests, it has been proved that there is no expression of NIS in cancer cells (which forms a thyroid carcinoma). Nevertheless, thanks to immunohistochemical techniques it is known that NIS is not functional in these cells, since it is mainly localized in the cytosol, and not in the basolateral membrane. [29]

There is also a connection between the V600E mutation of the BRAF oncogene and papillary thyroid cancer that cannot concentrate iodine into its follicular cells. [30]

Use with radioiodine (131I)

The main goal for the treatment of non-thyroid carcinoma is the research of less aggressive procedures that could also provide less toxicity. [31] One of these therapies is based on transferring NIS in cancer cells of different origin (breast, colon, prostate...) using adenoviruses or retroviruses (viral vectors). This genetic technique is called gene targeting. [32] [33] Once NIS is transferred in these cells, the patient is treated with radioiodine (131I), being the result a low cancer cell survival rate. Therefore, a lot is expected from these therapies. [34]

See also

Related Research Articles

<span class="mw-page-title-main">Hyperthyroidism</span> Thyroid gland disease that involves an overproduction of thyroid hormone

Hyperthyroidism is the condition that occurs due to excessive production of thyroid hormones by the thyroid gland. Thyrotoxicosis is the condition that occurs due to excessive thyroid hormone of any cause and therefore includes hyperthyroidism. Some, however, use the terms interchangeably. Signs and symptoms vary between people and may include irritability, muscle weakness, sleeping problems, a fast heartbeat, heat intolerance, diarrhea, enlargement of the thyroid, hand tremor, and weight loss. Symptoms are typically less severe in the elderly and during pregnancy. An uncommon but life-threatening complication is thyroid storm in which an event such as an infection results in worsening symptoms such as confusion and a high temperature; this often results in death. The opposite is hypothyroidism, when the thyroid gland does not make enough thyroid hormone.

<span class="mw-page-title-main">Thyroid</span> Endocrine gland in the neck; secretes hormones that influence metabolism

The thyroid, or thyroid gland, is an endocrine gland in vertebrates. In humans, it is in the neck and consists of two connected lobes. The lower two thirds of the lobes are connected by a thin band of tissue called the isthmus (PL: isthmi). The thyroid gland is a butterfly-shaped gland located in the neck below the Adam's apple. Microscopically, the functional unit of the thyroid gland is the spherical thyroid follicle, lined with follicular cells (thyrocytes), and occasional parafollicular cells that surround a lumen containing colloid. The thyroid gland secretes three hormones: the two thyroid hormones – triiodothyronine (T3) and thyroxine (T4) – and a peptide hormone, calcitonin. The thyroid hormones influence the metabolic rate and protein synthesis and growth and development in children. Calcitonin plays a role in calcium homeostasis. Secretion of the two thyroid hormones is regulated by thyroid-stimulating hormone (TSH), which is secreted from the anterior pituitary gland. TSH is regulated by thyrotropin-releasing hormone (TRH), which is produced by the hypothalamus.

<span class="mw-page-title-main">Hypothyroidism</span> Endocrine disease

Hypothyroidism is a disorder of the endocrine system in which the thyroid gland does not produce enough thyroid hormone. It can cause a number of symptoms, such as poor ability to tolerate cold, a feeling of tiredness, constipation, slow heart rate, depression, and weight gain. Occasionally there may be swelling of the front part of the neck due to goitre. Untreated cases of hypothyroidism during pregnancy can lead to delays in growth and intellectual development in the baby or congenital iodine deficiency syndrome.

Thyroid-stimulating hormone (also known as thyrotropin, thyrotropic hormone, or abbreviated TSH) is a pituitary hormone that stimulates the thyroid gland to produce thyroxine (T4), and then triiodothyronine (T3) which stimulates the metabolism of almost every tissue in the body. It is a glycoprotein hormone produced by thyrotrope cells in the anterior pituitary gland, which regulates the endocrine function of the thyroid.

<span class="mw-page-title-main">Thyroid follicular cell</span>

Thyroid follicular cells (also called thyroid epithelial cells or thyrocytes) are the major cell type in the thyroid gland, and are responsible for the production and secretion of the thyroid hormones thyroxine (T4) and triiodothyronine (T3). They form the single layer of cuboidal epithelium that makes up the outer structure of the almost spherical thyroid follicle.

<span class="mw-page-title-main">Hashimoto's thyroiditis</span> Autoimmune disease

Hashimoto's thyroiditis, also known as chronic lymphocytic thyroiditis and Hashimoto's disease, is an autoimmune disease in which the thyroid gland is gradually destroyed. Early on, symptoms may not be noticed. Over time, the thyroid may enlarge, forming a painless goiter. Some people eventually develop hypothyroidism with accompanying weight gain, fatigue, constipation, depression, hair loss, and general pains. After many years the thyroid typically shrinks in size. Potential complications include thyroid lymphoma. Furthermore, because it is common for untreated patients of Hashimoto's to develop hypothyroidism, further complications can include, but are not limited to, high cholesterol, heart disease, heart failure, high blood pressure, myxedema, and potential pregnancy problems.

<span class="mw-page-title-main">Wolff–Chaikoff effect</span> Effect of iodine on the thyroid

The Wolff–Chaikoff effect is a presumed reduction in thyroid hormone levels caused by ingestion of a large amount of iodine.

<span class="mw-page-title-main">Thyroid peroxidase</span> Enzyme expressed mainly in the thyroid gland

Thyroid peroxidase, also called thyroperoxidase (TPO) or iodide peroxidase, is an enzyme expressed mainly in the thyroid where it is secreted into colloid. Thyroid peroxidase oxidizes iodide ions to form iodine atoms for addition onto tyrosine residues on thyroglobulin for the production of thyroxine (T4) or triiodothyronine (T3), the thyroid hormones. In humans, thyroperoxidase is encoded by the TPO gene.

<span class="mw-page-title-main">Thyroid disease</span> Medical condition

Thyroid disease is a medical condition that affects the function of the thyroid gland. The thyroid gland is located at the front of the neck and produces thyroid hormones that travel through the blood to help regulate many other organs, meaning that it is an endocrine organ. These hormones normally act in the body to regulate energy use, infant development, and childhood development.

<span class="mw-page-title-main">Toxic multinodular goitre</span> Medical condition

Toxic multinodular goiter (TMNG), also known as multinodular toxic goiter (MNTG), is an active multinodular goiter associated with hyperthyroidism.

The thyroid hormone receptor (TR) is a type of nuclear receptor that is activated by binding thyroid hormone. TRs act as transcription factors, ultimately affecting the regulation of gene transcription and translation. These receptors also have non-genomic effects that lead to second messenger activation, and corresponding cellular response.

<span class="mw-page-title-main">PAX8</span> Mammalian protein found in Homo sapiens

Paired box gene 8, also known as PAX8, is a protein which in humans is encoded by the PAX8 gene.

<span class="mw-page-title-main">IGSF1</span> Protein-coding gene in the species Homo sapiens

Immunoglobulin superfamily, member 1 is a plasma membrane glycoprotein encoded by the IGSF1 gene, which maps to the X chromosome in humans and other mammalian species.

<span class="mw-page-title-main">PTTG1IP</span> Protein-coding gene in the species Homo sapiens

Pituitary tumor-transforming gene 1 protein-interacting protein (PTTG1), also known as PTTG1-binding factor (PBF), is a poorly characterised protein that in humans is encoded by the PTTG1IP gene located within the chromosomal region 21q22.3.

<span class="mw-page-title-main">Thyroid hormones</span> Hormones produced by the thyroid gland

Thyroid hormones are any hormones produced and released by the thyroid gland, namely triiodothyronine (T3) and thyroxine (T4). They are tyrosine-based hormones that are primarily responsible for regulation of metabolism. T3 and T4 are partially composed of iodine, derived from food. A deficiency of iodine leads to decreased production of T3 and T4, enlarges the thyroid tissue and will cause the disease known as simple goitre.

<span class="mw-page-title-main">Iodotyrosine deiodinase</span> Protein-coding gene in the species Homo sapiens

Iodotyrosine deiodinase, also known as iodotyrosine dehalogenase 1, is a type of deiodinase enzyme that scavenges iodide by removing it from iodinated tyrosine residues in the thyroid gland. These iodinated tyrosines are produced during thyroid hormone biosynthesis. The iodide that is scavenged by iodotyrosine deiodinase is necessary to again synthesize the thyroid hormones. After synthesis, the thyroid hormones circulate through the body to regulate metabolic rate, protein expression, and body temperature. Iodotyrosine deiodinase is thus necessary to keep levels of both iodide and thyroid hormones in balance.

<span class="mw-page-title-main">Iodine in biology</span> Use of Iodine by organisms

Iodine is an essential trace element in biological systems. It has the distinction of being the heaviest element commonly needed by living organisms as well as the second-heaviest known to be used by any form of life. It is a component of biochemical pathways in organisms from all biological kingdoms, suggesting its fundamental significance throughout the evolutionary history of life.

Antithyroid autoantibodies (or simply antithyroid antibodies) are autoantibodies targeted against one or more components on the thyroid. The most clinically relevant anti-thyroid autoantibodies are anti-thyroid peroxidase antibodies (anti-TPO antibodies, TPOAb), thyrotropin receptor antibodies (TRAb) and thyroglobulin antibodies (TgAb). TRAb's are subdivided into activating, blocking and neutral antibodies, depending on their effect on the TSH receptor. Anti-sodium/iodide (Anti–Na+/I) symporter antibodies are a more recent discovery and their clinical relevance is still unknown. Graves' disease and Hashimoto's thyroiditis are commonly associated with the presence of anti-thyroid autoantibodies. Although there is overlap, anti-TPO antibodies are most commonly associated with Hashimoto's thyroiditis and activating TRAb's are most commonly associated with Graves' disease. Thyroid microsomal antibodies were a group of anti-thyroid antibodies; they were renamed after the identification of their target antigen (TPO).

Measles virus encoding the human thyroidal sodium iodide symporter or MV-NIS is an attenuated oncolytic Edmonston (Ed) strain of measles virus.

Nancy Carrasco is a professor in, and the chair of, the Department of Molecular Physiology and Biophysics at Vanderbilt University. Carrasco has conducted research in the fields of biochemistry, biophysics, molecular physiology, molecular endocrinology, and cancer. She cloned the sodium/iodide symporter (NIS), a breakthrough in thyroid pathophysiology with ramifications for many other fields, including structure/function of transport proteins, molecular endocrinology, gene transfer studies, cancer, and public health.

References

  1. 1 2 3 GRCh38: Ensembl release 89: ENSG00000105641 - Ensembl, May 2017
  2. 1 2 3 GRCm38: Ensembl release 89: ENSMUSG00000000792 - Ensembl, May 2017
  3. "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. Glossary, UniProt Consortium
  6. "Entrez Gene: SLC5A5 solute carrier family 5 (sodium iodide symporter), member 5".
  7. Dai G, Levy O, Carrasco N (February 1996). "Cloning and characterization of the thyroid iodide transporter". Nature. 379 (6564): 458–460. Bibcode:1996Natur.379..458D. doi:10.1038/379458a0. PMID   8559252. S2CID   4366019.
  8. Smanik PA, Ryu KY, Theil KS, Mazzaferri EL, Jhiang SM (August 1997). "Expression, exon-intron organization, and chromosome mapping of the human sodium iodide symporter". Endocrinology. 138 (8): 3555–3558. doi: 10.1210/endo.138.8.5262 . PMID   9231811.
  9. 1 2 Dohán O, De la Vieja A, Paroder V, Riedel C, Artani M, Reed M, et al. (February 2003). "The sodium/iodide Symporter (NIS): characterization, regulation, and medical significance". Endocrine Reviews. 24 (1): 48–77. doi: 10.1210/er.2001-0029 . PMID   12588808.
  10. Yavuz S, Puckett Y (2022). "Iodine-131 Uptake Study". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID   32644709 . Retrieved 2023-01-05.
  11. Nilsson M (2001). "Iodide handling by the thyroid epithelial cell". Experimental and Clinical Endocrinology & Diabetes. 109 (1): 13–17. doi:10.1055/s-2001-11014. PMID   11573132.
  12. Cavalieri RR (April 1997). "Iodine metabolism and thyroid physiology: current concepts". Thyroid. 7 (2): 177–181. doi:10.1089/thy.1997.7.177. PMID   9133680.
  13. Chen I, Lui F (2022). "Physiology, Active Transport". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID   31613498 . Retrieved 2023-01-05.
  14. Pirahanchi Y, Tariq MA, Jialal I (2022). "Physiology, Thyroid". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID   30137850 . Retrieved 2023-01-05.
  15. Harun-Or-Rashid M, Asai M, Sun XY, Hayashi Y, Sakamoto J, Murata Y (June 2010). "Effect of thyroid statuses on sodium/iodide symporter (NIS) gene expression in the extrathyroidal tissues in mice". Thyroid Research. 3 (1): 3. doi:10.1186/1756-6614-3-3. PMC   2901223 . PMID   20529371.
  16. Ząbczyńska M, Kozłowska K, Pocheć E (September 2018). "Glycosylation in the Thyroid Gland: Vital Aspects of Glycoprotein Function in Thyrocyte Physiology and Thyroid Disorders". International Journal of Molecular Sciences. 19 (9): 2792. doi: 10.3390/ijms19092792 . PMC   6163523 . PMID   30227620.
  17. Ryan J, Curran CE, Hennessy E, Newell J, Morris JC, Kerin MJ, Dwyer RM (January 2011). "The sodium iodide symporter (NIS) and potential regulators in normal, benign and malignant human breast tissue". PLOS ONE. 6 (1): e16023. Bibcode:2011PLoSO...616023R. doi: 10.1371/journal.pone.0016023 . PMC   3023714 . PMID   21283523.
  18. Waugh DT (March 2019). "Fluoride Exposure Induces Inhibition of Sodium/Iodide Symporter (NIS) Contributing to Impaired Iodine Absorption and Iodine Deficiency: Molecular Mechanisms of Inhibition and Implications for Public Health". International Journal of Environmental Research and Public Health. 16 (6): 1086. doi: 10.3390/ijerph16061086 . PMC   6466022 . PMID   30917615.
  19. Hallinger DR, Murr AS, Buckalew AR, Simmons SO, Stoker TE, Laws SC (April 2017). "Development of a screening approach to detect thyroid disrupting chemicals that inhibit the human sodium iodide symporter (NIS)". Toxicology in Vitro. 40: 66–78. doi:10.1016/j.tiv.2016.12.006. PMID   27979590.
  20. Wang J, Hallinger DR, Murr AS, Buckalew AR, Simmons SO, Laws SC, Stoker TE (May 2018). "High-Throughput Screening and Quantitative Chemical Ranking for Sodium-Iodide Symporter Inhibitors in ToxCast Phase I Chemical Library". Environmental Science & Technology. 52 (9): 5417–5426. Bibcode:2018EnST...52.5417W. doi:10.1021/acs.est.7b06145. PMC   6697091 . PMID   29611697.
  21. Kogai T, Brent GA (September 2012). "The sodium iodide symporter (NIS): regulation and approaches to targeting for cancer therapeutics". Pharmacology & Therapeutics. 135 (3): 355–370. doi:10.1016/j.pharmthera.2012.06.007. PMC   3408573 . PMID   22750642.
  22. Kopp P (August 2001). "The TSH receptor and its role in thyroid disease". Cellular and Molecular Life Sciences. 58 (9): 1301–1322. doi:10.1007/pl00000941. PMID   11577986. S2CID   24857215.
  23. Wang H, Xu J, Lazarovici P, Quirion R, Zheng W (2018). "cAMP Response Element-Binding Protein (CREB): A Possible Signaling Molecule Link in the Pathophysiology of Schizophrenia". Frontiers in Molecular Neuroscience. 11: 255. doi: 10.3389/fnmol.2018.00255 . PMC   6125665 . PMID   30214393.
  24. Ohno M, Zannini M, Levy O, Carrasco N, di Lauro R (March 1999). "The paired-domain transcription factor Pax8 binds to the upstream enhancer of the rat sodium/iodide symporter gene and participates in both thyroid-specific and cyclic-AMP-dependent transcription". Molecular and Cellular Biology. 19 (3): 2051–2060. doi:10.1128/mcb.19.3.2051. PMC   83998 . PMID   10022892.
  25. Riesco-Eizaguirre G, Rodríguez I, De la Vieja A, Costamagna E, Carrasco N, Nistal M, Santisteban P (November 2009). "The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer". Cancer Research. 69 (21): 8317–8325. doi:10.1158/0008-5472.CAN-09-1248. PMID   19861538.
  26. de Souza EC, Padrón AS, Braga WM, de Andrade BM, Vaisman M, Nasciutti LE, et al. (July 2010). "MTOR downregulates iodide uptake in thyrocytes". The Journal of Endocrinology. 206 (1): 113–120. doi:10.1677/JOE-09-0436. PMID   20392814.
  27. Carvalho DP, Ferreira AC (July 2007). "The importance of sodium/iodide symporter (NIS) for thyroid cancer management". Arquivos Brasileiros de Endocrinologia e Metabologia. 51 (5): 672–682. doi: 10.1590/s0004-27302007000500004 . PMID   17891230.
  28. De La Vieja A, Dohan O, Levy O, Carrasco N (July 2000). "Molecular analysis of the sodium/iodide symporter: impact on thyroid and extrathyroid pathophysiology". Physiological Reviews. 80 (3): 1083–1105. doi:10.1152/physrev.2000.80.3.1083. PMID   10893432.
  29. Tavares C, Coelho MJ, Eloy C, Melo M, da Rocha AG, Pestana A, et al. (January 2018). "NIS expression in thyroid tumors, relation with prognosis clinicopathological and molecular features". Endocrine Connections. 7 (1): 78–90. doi:10.1530/EC-17-0302. PMC   5754505 . PMID   29298843.
  30. Frasca F, Nucera C, Pellegriti G, Gangemi P, Attard M, Stella M, et al. (March 2008). "BRAF(V600E) mutation and the biology of papillary thyroid cancer". Endocrine-Related Cancer. 15 (1): 191–205. doi:10.1677/ERC-07-0212. PMID   18310287. S2CID   18851007.
  31. Haddad RI, Nasr C, Bischoff L, Busaidy NL, Byrd D, Callender G, et al. (December 2018). "NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018". Journal of the National Comprehensive Cancer Network. 16 (12): 1429–1440. doi: 10.6004/jnccn.2018.0089 . PMID   30545990. S2CID   56485177.
  32. Barzaman K, Karami J, Zarei Z, Hosseinzadeh A, Kazemi MH, Moradi-Kalbolandi S, et al. (July 2020). "Breast cancer: Biology, biomarkers, and treatments". International Immunopharmacology. 84: 106535. doi:10.1016/j.intimp.2020.106535. PMID   32361569. S2CID   218491293.
  33. Xin L (2019). "Cells of Origin for Prostate Cancer". Advances in Experimental Medicine and Biology. 1210: 67–86. doi:10.1007/978-3-030-32656-2_4. ISBN   978-3-030-32655-5. PMID   31900905. S2CID   209748179.
  34. Spitzweg C, O'Connor MK, Bergert ER, Tindall DJ, Young CY, Morris JC (November 2000). "Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter". Cancer Research. 60 (22): 6526–6530. PMID   11103823.

Further reading